Breaking News, Collaborations & Alliances

Actinium, Astellas Form Research Partnership

Will utilize Actinium's AWE Technology Platform to generate Actinium Radio-Conjugates on selected Astellas targeting agents

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Actinium Pharmaceuticals has entered into a research and option agreement with Astellas to develop Actinium-225 Radio-Conjugates (ARCs) using its Actinium Warhead Enabling (AWE) Platform Technology. Under this collaboration, Actinium will utilize its AWE Platform to conjugate and label selected Astellas targeting agents with the actinium-225 (225Ac) payload. Actinium will also be responsible for conducting preclinical validation studies on the novel ARCs generated. Actinium will receive a seven-...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters